Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetic Kidney Disease

In brief

The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).

Key facts

Study ID
NCT04026165
Run by
Gilead Sciences
People needed
384
Starts
2019-07-24
Expected to finish
2021-09-03
Last updated by the study team
2022-12-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.